AlphAIAlphAI — Financial news for AI agents
dairyreporter.com$PRGO

Perrigo exits infant formula sector with sale to MeridianMade worth up to $175m

Perrigo has agreed to sell its infant formula business to MeridianMade for up to $175 million, including $40 million in cash and up to $135 million contingent on future performance milestones. The deal, expected to close in early 2027, will allow Perrigo to focus on its consumer self-care portfolio and improve its margin profile. Perrigo is a major player in the global infant formula market, ranking third in the US and Canada.

Original reporting
dairyreporter.com
Published Nov 2, 2026, 3:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 7:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Perrigo exits infant formula sector with sale to MeridianMade worth up to $175m — source image
Source · dairyreporter.com
Decision brief

The 30-second read

$PRGOBullishHigh
01

Why it matters

Divesting the infant formula unit should improve Perrigo's profitability metrics and free cash flow, potentially supporting a share price rally.

02

Market read

The transaction is a material M&A event for Perrigo, likely influencing its stock valuation and sector positioning.

03

What to watch

Regulatory approvals and integration risks for MeridianMade could delay or diminish the expected benefits of the transaction.

Relevance 7/10Novelty 8/10Timing: immediate

Background

Perrigo is a leading OTC consumer health company; the infant formula segment represented a sizable but non‑core business.

Company-level read

Ticker impact

$PRGOBullishHigh confidence
Context

Perrigo announced a definitive agreement to sell its infant formula business to MeridianMade for up to $175 million, a divestiture that should improve margins and reduce capital expenditures.

Expected impact

likely modest upside as the market prices in improved profitability and lower capex

Evidence & confidence

Divestitures that boost margins and cut capex are typically viewed favorably by investors, especially when the deal size is material for a mid‑cap company.

Market effects

Sector

The infant formula market may see a shift in supply dynamics as MeridianMade expands its footprint, but the broader consumer self‑care sector could benefit from Perrigo's sharper focus.

Regional

U.S. consumer health segment may see a slight re‑rating of Perrigo, while North American infant formula suppliers could feel competitive pressure.

Global

Limited to the consumer health and infant nutrition segments; no broad market impact.

Counterpoint

What could challenge this read

The sale could signal that Perrigo's infant formula business was underperforming, raising concerns about the health of its remaining portfolio.

Key entities

  • company
    Perrigo Company plc

    US‑listed consumer health company (ticker PRGO) selling its infant formula business.

  • company
    MeridianMade

    Private contract manufacturer focused on infant nutrition acquiring Perrigo's infant formula business.

Read at source← All news

StoryPerrigo to sell infant formula business to MeridianMade for up to $175 million

Also covered by

1 outlet

Related articles

$PRGOMed

Perrigo Q3 Earnings Call Highlights

Perrigo (PRGO) reported Q3 earnings with net sales declines in self-care and specialty care segments. Adjusted EPS fell to 61 cents, with a lower tax rate providing some benefit. The company expects 2026 sales declines and adjusted EPS of $2.15-$2.35. Perrigo is divesting infant formula and other businesses to simplify operations and reduce debt. Cash and debt at quarter-end were $437M and $3.3B, respectively.

finance.yahoo.com
$PRGOHigh

Perrigo Sets 2026 All-In Adjusted EPS Outlook at $2.25 to $2.45

Perrigo Company plc set its 2026 adjusted diluted EPS outlook at $2.25 to $2.45, excluding its infant formula unit, which it classified as discontinued operations. Core EPS is expected at $2.15 to $2.35, with core sales declining 2.5% to 3.6% and an adjusted operating margin of 14% to 15%. The company plans to sell the unit to MeridianMade for up to $175 million, with $40 million upfront.

tokenpost.com
$PRGOMed

Perrigo Co PLC (PRGO) (Q3 2026) Earnings Call Highlights: Margin Gains and Share Growth

Perrigo (PRGO) reported Q3 2026 core net sales declined 1.7% YoY, with organic sales down 1.1%. Adjusted gross margin fell 140 bps to 37.9%. The company updated its 2026 outlook downward, citing retailer inventory positioning and European softness. Interim CEO Albert Manzone highlighted share gains, innovation, and e-commerce growth as priorities. The infant formula divestiture is complete, and oral care is under strategic review.

finance.yahoo.com
$PRGOMed

Perrigo (PRGO) Q3 2026 Earnings Call Transcript

Perrigo (PRGO) reported Q3 2026 earnings, highlighting operational improvements and a strategic focus on simplifying the business. The company saw sequential improvements in core net sales and operating margins, with a 1.7% decline in sales and a 14.3% operating margin. Perrigo announced the sale of its infant formula business and updated its 2026 outlook, reflecting divestments and market conditions.

finance.yahoo.com
$PRGOMed

Perrigo Company plc Q3 2026 Earnings Call Summary

Perrigo reported Q3 2026 improvements in core adjusted operating margins (12.8% to 14.3%) due to its Three-S plan. The company is simplifying its portfolio, including divesting the infant formula business, to focus on higher-margin categories. Market share gains in U.S. and European OTC brands were noted, along with e-commerce expansion. Management updated 2026 and 2027 outlooks, emphasizing debt reduction and operational improvements. Q3 results included a $4.5M one-time tariff benefit.

finance.yahoo.com